Jeffrey W. Clark

41.0k total citations · 5 hit papers
351 papers, 16.8k citations indexed

About

Jeffrey W. Clark is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Jeffrey W. Clark has authored 351 papers receiving a total of 16.8k indexed citations (citations by other indexed papers that have themselves been cited), including 213 papers in Oncology, 106 papers in Pulmonary and Respiratory Medicine and 73 papers in Surgery. Recurrent topics in Jeffrey W. Clark's work include Pancreatic and Hepatic Oncology Research (74 papers), Colorectal Cancer Treatments and Studies (66 papers) and Lung Cancer Treatments and Mutations (45 papers). Jeffrey W. Clark is often cited by papers focused on Pancreatic and Hepatic Oncology Research (74 papers), Colorectal Cancer Treatments and Studies (66 papers) and Lung Cancer Treatments and Mutations (45 papers). Jeffrey W. Clark collaborates with scholars based in United States, Italy and South Korea. Jeffrey W. Clark's co-authors include David P. Ryan, Eunice L. Kwak, Dan G. Duda, Charles S. Fuchs, Rakesh K. Jain, Peter C. Enzinger, Lawrence S. Blaszkowsky, Andrew X. Zhu, Jay S. Loeffler and Matthew H. Kulke and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Jeffrey W. Clark

334 papers receiving 16.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

2006 823 citations Rakesh K. Jain, Dan G. Duda et al. profile →
Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor

2010 604 citations Eunice L. Kwak, Jeffrey W. Clark et al. profile →
Frequent Mutation of Isocitrate Dehydrogenase(IDH)1andIDH2in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping

2011 548 citations Darrell R. Borger, Marek Ancukiewicz et al. The Oncologist profile →
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

2019 365 citations Benjamin Solomon, A. John Iafrate et al. Annals of Oncology profile →
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma

2018 362 citations Janet E. Murphy, Jennifer Y. Wo et al. profile →

Peers

Countries citing papers authored by Jeffrey W. Clark

Since Specialization

Citations

This map shows the geographic impact of Jeffrey W. Clark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey W. Clark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey W. Clark more than expected).

Fields of papers citing papers by Jeffrey W. Clark

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey W. Clark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey W. Clark. The network helps show where Jeffrey W. Clark may publish in the future.

Co-authorship network of co-authors of Jeffrey W. Clark

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey W. Clark. A scholar is included among the top collaborators of Jeffrey W. Clark based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey W. Clark. Jeffrey W. Clark is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	SBRT with ipilimumab and nivolumab to metastatic MSS colorectal and pancreatic cancer: A pooled analysis of four prospective phase II trials. 2024 ·Journal of Clinical Oncology ·Hannah Roberts, (unknown), Beow Y. Yeap, Julie L. Koenig, Aparna R. Parikh, Jeffrey W. Clark, David P. Ryan, Jill N. Allen, Colin D. Weekes, Lawrence S. Blaszkowsky, Priyadarshini Pathak, Lorraine C. Drapek, Leilana Ly, Theodore S. Hong, Jennifer Y. Wo	0
2	664P Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors 2023 ·Annals of Oncology ·Ryan B. Corcoran, T. Khanh, James M. Cleary, Aparna R. Parikh, Oladapo Yeku, Colin D. Weekes, Leanne G. Ahronian, Gianluca Mauri, Ju Tian, Joan S. Brugge, Dejan Juric, K. T. Flaherty, Ryan J. Sullivan, Jeffrey W. Clark, Rebecca S. Heist, U. Matulonis, (unknown), Geoffrey I. Shapiro	1
3	Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic Cancer 2023 ·Clinical Cancer Research ·Yves Boucher, Jessica M. Posada, Sonu Subudhi, Ashwin S. Kumar, Spencer R. Rosario, Liqun Gu, Heena Kumra, Mari Mino–Kenudson, Nilesh P. Talele, Dan G. Duda, Dai Fukumura, Jennifer Y. Wo, Jeffrey W. Clark, David P. Ryan, Carlos Fernández‐del Castillo, Theodore S. Hong, Mikäel J. Pittet, Rakesh K. Jain	30
4	Evolutionary Analysis of Pre- and Post-treatment Molecular Diversity in Rectal Cancer Patients Receiving Neoadjuvant Chemoradiation (CRT) and a KRAS Mutation-targeted Radiosensitizer 2020 ·International Journal of Radiation OncologyBiologyPhysics ·Sophia C. Kamran, Christine E. Eyler, Jochen K. Lennerz, Jennifer Y. Wo, (unknown), Hui Zheng, Darrel R. Borger, Jill N. Allen, David L. Berger, James C. Cusack, (unknown), Andrew X. Zhu, Jeffrey W. Clark, Jason A. Efstathiou, Henning Willers, (unknown), Kevin M. Haigis, Theodore S. Hong	0
5	Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study 2019 ·International Journal of Radiation OncologyBiologyPhysics ·Jennifer Y. Wo, John P. Plastaras, James M. Metz, Wenqing Jiang, Beow Y. Yeap, Lorraine C. Drapek, Judith Adams, Christian Baglini, David P. Ryan, Janet E. Murphy, Aparna R. Parikh, Jill N. Allen, Jeffrey W. Clark, Lawrence S. Blaszkowsky, Thomas F. DeLaney, Edgar Ben‐Josef, Theodore S. Hong	21
6	OA12.02 Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer 2018 ·Journal of Thoracic Oncology ·Alexander Drilon, Jeffrey W. Clark, Jared Weiss, Sai‐Hong Ignatius Ou, D. Ross Camidge, Benjamin Solomon, Gregory A. Otterson, Liza C. Villaruz, Gregory J. Riely, Rebecca S. Heist, Geoffrey I. Shapiro, Danielle Murphy, (unknown), Tiziana Usari, (unknown), Keith D. Wilner, Paul K. Paik	24
7	Irradiation of anatomically defined pelvic subsites and acute hematologic toxicity in anal cancer patients undergoing chemoradiation 2017 ·Practical Radiation Oncology ·Brent S. Rose, Devarati Mitra, Theodore S. Hong, Kyung‐Wook Jee, Andrzej Niemierko, (unknown), Lawrence S. Blaszkowsky, Jill N. Allen, Janet E. Murphy, Jeffrey W. Clark, David P. Ryan, Jennifer Y. Wo	10
8	Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors 2015 ·Clinical Cancer Research ·John Sarantopoulos, Geoffrey I. Shapiro, Roger B. Cohen, Jeffrey W. Clark, John Kauh, Glen J. Weiss, James M. Cleary, Devalingam Mahalingam, Michael D. Pickard, Hélène M. Faessel, Allison Berger, Kristine Burke, George Mulligan, Bruce J. Dezube, R. Donald Harvey	139
9	Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET -Amplified Esophagogastric Cancer 2015 ·Cancer Discovery ·Eunice L. Kwak, Leanne G. Ahronian, Giulia Siravegna, Benedetta Mussolin, Darrell R. Borger, Jason T. Godfrey, Nicholas A. Jessop, Jeffrey W. Clark, Lawrence S. Blaszkowsky, David P. Ryan, Jochen K. Lennerz, A. John Iafrate, Alberto Bardelli, Theodore S. Hong, Ryan B. Corcoran	138
10	Familial Gastric Cancers 2015 ·The Oncologist ·Namrata Setia, Jeffrey W. Clark, Dan G. Duda, Theodore S. Hong, Eunice L. Kwak, John T. Mullen, Gregory Y. Lauwers	42
11	Crizotinib Treatment in Patients (PTS) with Advanced ROS1-Rearranged Non-Small Cell Lung Cancer (NSCLC) 2013 ·Annals of Oncology ·S.-H.I. Ou, (unknown), D. Ross Camidge, Gregory J. Riely, Ravi Salgia, Geoffrey I. Shapiro, Jeffrey W. Clark, L. Tye, A. John Iafrate, Alice T. Shaw	4
12	Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors 2012 ·Journal of Clinical Oncology ·Jennifer A. Chan, Keith Stuart, Craig C. Earle, Jeffrey W. Clark, Pankaj Bhargava, Rebecca A. Miksad, Lawrence S. Blaszkowsky, Peter C. Enzinger, Jeffrey A. Meyerhardt, Hui Zheng, Charles S. Fuchs, Matthew H. Kulke	207
13	A Multicenter Retrospective Study on Clinical Characteristics, Treatment Patterns, and Outcome in Elderly Patients with Hepatocellular Carcinoma 2011 ·The Oncologist ·Olga Kozyreva, (unknown), Jeffrey W. Clark, Hong Wang, K. P. Theall, David P. Ryan, Andrew X. Zhu	26
14	Exploratory Analysis of Early Toxicity of Sunitinib in Advanced Hepatocellular Carcinoma Patients: Kinetics and Potential Biomarker Value 2010 ·Clinical Cancer Research ·Andrew X. Zhu, Dan G. Duda, Marek Ancukiewicz, Emmanuelle di Tomaso, Jeffrey W. Clark, Rebecca A. Miksad, Charles S. Fuchs, David P. Ryan, Rakesh K. Jain	25
15	Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma 2007 ·Cancer ·Andrew X. Zhu, Keith Stuart, Lawrence S. Blaszkowsky, Alona Muzikansky, Donald P. Reitberg, Jeffrey W. Clark, Peter C. Enzinger, Pankaj Bhargava, Jeffrey A. Meyerhardt, Kerry Horgan, Charles S. Fuchs, David P. Ryan	190
16	A Phase II Trial of Irinotecan and Cisplatin in Patients with Metastatic Neuroendocrine Tumors 2006 ·Digestive Diseases and Sciences ·Matthew H. Kulke, Bingyan Wu, David P. Ryan, Peter C. Enzinger, Andrew X. Zhu, Jeffrey W. Clark, Craig C. Earle, Ann Michelini, Charles S. Fuchs	68
17	Long-term Results of Intraoperative Electron Beam Irradiation (IOERT) for Patients With Unresectable Pancreatic Cancer 2005 ·Annals of Surgery ·Christopher G. Willett, Carlos Fernández del Castillo, Helen A. Shih, Saveli Goldberg, Peter J. Biggs, Jeffrey W. Clark, Gregory Y. Lauwers, David P. Ryan, Andrew X. Zhu, Andrew L. Warshaw	68
18	Double bond in the side chain of 1α,25-dihydroxy-22-ene-vitamin D3 is reduced during its metabolism: studies in chronic myeloid leukemia (RWLeu-4) cells and rat kidney 2001 ·The Journal of Steroid Biochemistry and Molecular Biology ·D.Sunita Rao, Dhruv R Balkundi, Milan R. Uskoković, Kou‐Yi Tserng, Jeffrey W. Clark, Ronald L. Horst, G. Satyanarayana Reddy	4
19	Effects of tyrosine kinase inhibitors on the proliferation of human breast cancer cell lines and proteins important in the RAS signaling pathway 1996 ·International Journal of Cancer ·Jeffrey W. Clark, (unknown), (unknown), A. Raymond Frackelton	5
20	Effects of tyrosine kinase inhibitors on the proliferation of human breast cancer cell lines and proteins important in the RAS signaling pathway 1996 ·International Journal of Cancer ·Jeffrey W. Clark, (unknown), (unknown), A. Raymond Frackelton	47

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact